FindTrial
Sign In

CHF 5074 2x

DRUG4 trials

Sponsors

CERESPIR, Chiesi Farmaceutici S.p.A.

Conditions

Alzheimer's Disease

Phase 2

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
CompletedNCT01303744
CERESPIRAlzheimer's Disease
Start: 2011-03-31End: 2012-04-30Updated: 2016-01-11
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
CompletedNCT01421056
Chiesi Farmaceutici S.p.A.Alzheimer's Disease
Start: 2011-07-31End: 2012-11-30Updated: 2014-02-06
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
CompletedNCT01602393
Chiesi Farmaceutici S.p.A.Alzheimer's Disease
Start: 2012-05-31End: 2013-10-31Updated: 2014-02-06
Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
WithdrawnNCT01723670
CERESPIRAlzheimer's Disease
Start: 2012-12-31End: 2016-03-31Updated: 2015-02-10